AMAL
Amalgamated Financial Corp.
AMAL's outlook is improving, though it still trails on the overall score.
MS
Morgan Stanley
MS has the edge over AMAL overall, supported by stronger valuation and stronger modeled upside.
AMAL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
AMAL's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like AMAL.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
AMAL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.7x | $31.28 | -38% |
| Fair | 9.8x | $39.80 | -21% |
| Forward | 11x | $50.08 | — |
| Expensive | 12x | $47.33 | -5.5% |
| Current | 12x | $50.08 | — |
Historical ranges are pointers, not guarantees.
AMAL has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
AMAL Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for AMAL, with profitability improving.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
AMAL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.46 | +9.5% |
| Q3 2026 | $4.07 | +23% |
| Q2 2026 | $3.75 | +13% |
| Q1 2026 | $3.44 | +2.4% |
| Q4 2025 | $3.41 | -0.9% |
| Q3 2025 | $3.31 | -2.6% |
| Q2 2025 | $3.33 | +3.1% |
| Q1 2025 | $3.36 | +9.8% |
| Q4 2024 | $3.44 | +20% |
AMAL earned $4.07 per share over the past year, up 23% from the year before.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over AMAL on earnings, with more consistent year-over-year improvement.
AMAL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $101.7M | +19% |
| Q2 2026 | $98.4M | +22% |
| Q1 2026 | $93.4M | +21% |
| Q4 2025 | $85.2M | +9.4% |
| Q3 2025 | $85.6M | +5.6% |
| Q2 2025 | $80.9M | +3.2% |
| Q1 2025 | $77M | -1.6% |
| Q4 2024 | $77.9M | +1.5% |
AMAL's revenue has grown year over year for six quarters in a row: $102M last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 48% | +5.5 points |
| Q2 2026 | 47% | +3.6 points |
| Q1 2026 | 36% | -8.7 points |
| Q4 2025 | 39% | -3.4 points |
| Q3 2025 | 43% | -4.3 points |
| Q2 2025 | 44% | -1.8 points |
| Q1 2025 | 45% | -4.1 points |
| Q4 2024 | 42% | -3.5 points |
AMAL has the edge over MS on profitability, with a higher operating margin.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over AMAL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
AMAL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33M | -14% |
| Q2 2026 | $19.6M | -24% |
| Q1 2026 | $50.7M | +56% |
| Q4 2025 | $38M | +34% |
| Q3 2025 | $38.3M | +8.8% |
| Q2 2025 | $25.6M | -7.7% |
| Q1 2025 | $32.5M | +4.5% |
| Q4 2024 | $28.3M | +88% |
AMAL has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
AMAL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +52K shares |
| 1 year | -0.6% | -170K shares |
| 3 years | -1.1% | -349K shares |
| 5 years | -3.9% | -1.2M shares |
AMAL has 30M diluted shares, down 0.6% from a year ago, with $18M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6.5M |
| Q2 2026 | — |
| Q1 2026 | $2.8M |
| Q4 2025 | $8.7M |
| Q3 2025 | $10.4M |
| Q2 2025 | $9.7M |
| Q1 2025 | $3.5M |
| Q4 2024 | $845,000 |
AMAL spent $18M buying back its own shares over the past year, down 26% from the year before.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over AMAL on shareholder dilution, with a more favorable share count trend.
AMAL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 1.7x | Healthy |
AMAL has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
AMAL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.6 | Neutral |
| Stochastic | 66.4 | Neutral |
AMAL's weekly RSI is 63 (neutral) and its Stochastic is 66 (neutral).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
AMAL PE vs Financial Services Sector
| Metric | AMAL | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 5.5% below |
| PE % | 89 | 63 | 26 pts above |
AMAL has the edge over MS on valuation relative to its sector.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
AMAL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $48.7 | 2.8% above |
| 20 week MA | $48.6 | 3.1% above |
| 50 week MA | $42.8 | 17% above |
| 100 week MA | $36.5 | 37% above |
| 200 week MA | $30.1 | 66% above |
AMAL has the edge over MS on trend strength, trading above more of its moving averages.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
AMAL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.6 | $13.6 | -30% |
| 2021 | $13.6 | $16.7 | +22% |
| 2022 | $16.7 | $23.1 | +39% |
| 2023 | $23.1 | $26.9 | +17% |
| 2024 | $26.9 | $33.7 | +25% |
| 2025 | $33.7 | $32.7 | -3% |
| 2026 YTD | $32.7 | $50.1 | +53% |
AMAL has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.